Patent estate

BeiGene — Patent Portfolio

2 drugs with active patents · 25 active patents · 0 expired · 1 biologic with BPCIA exclusivity

AI-enriched 23/25 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

§
Strategic Patent Estate Brief
AI-grounded executive summary · generated 2026-05-16

Verdict BeiGene's patent portfolio is strong, but faces a significant cliff in 2034 with 1 drug losing exclusivity, including Brukinsa, with a total of $0 in revenue at risk in the next 5 years.

Portfolio overview BeiGene has a total of 34 drugs in its portfolio, with 25 active US patents and 0 expired US patents. The average vulnerability score of its patents is 62, indicating a moderate level of vulnerability. The company has 4 ironclad patents and 17 vulnerable patents. Additionally, BeiGene has 1 biologic with BPCIA exclusivity.

Cliff calendar BeiGene faces a significant cliff in 2034, with 1 drug losing exclusivity, including Brukinsa. This is the only year in the next 5 years where a drug will lose exclusivity.

Most exposed drugs The top drug facing near-term loss of exclusivity is Brukinsa, with an earliest active patent expiry date of 2034-04-22, an average vulnerability score of 62, and no annual revenue data available. Brukinsa has 25 patents and is the only drug in the portfolio with a vulnerability score above 60.

Biologic exclusivity BeiGene has 1 biologic, TEVIMBRA, with BPCIA 12-year reference product exclusivity ending in 2036-03-13 (BLA number 761232).

Strategic implications BeiGene has $0 in revenue at risk in the next 5 years. The company should consider lifecycle moves such as subQ switches, label extensions, and combination filings to maximize revenue from its portfolio.

Sources: FDA Orange Book · FDA Purple Book · INPADOC family · USPTO · vulnerability scoring. Not legal advice.

Loss of exclusivity calendar · next 12 years

Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.

1 2034 1 2036 1 2037

Patent estate by drug

TEVIMBRA (islelizumab-jsgr)

🧬 BPCIA biologic exclusivity to 2036-03-13

Brukinsa (ZANUBRUTINIB)

Cliff 2034 · 8y
Method of Use 20 Composition of Matter 4 Formulation 1
  • US10570139 Vuln 75 2034-04-22
    This patent protects fused heterocyclic compounds that can be used to inhibit Bruton's tyrosine kinase and treat disorders mediated thereby.
  • US9447106 Vuln 75 2034-04-22
    This patent protects substituted pyrazolo[1,5-a]pyrimidine compounds, including Brukinsa, as Bruton's tyrosine kinase modulators.
  • US11142528 Vuln 75 2034-04-22
    This patent protects fused heterocyclic compounds that can be used to inhibit Bruton's tyrosine kinase and treat related disorders.
See all 25 patents →

Patent classification breakdown · active patents

By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.

  • Method of Use 20 patents
  • Composition of Matter 4 patents
  • Formulation 1 patent

Sources

  • FDA Orange Book — small-molecule patents listed against approved NDAs.
  • FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
  • USPTO Patent Public Search — title, abstract, claim text grounding.
  • AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track BeiGene's patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export